{ "items": [ "\n\n
\n \n 10 December 2020\n \n
\n\n \n \n \n\n \n \n \nEuropean Research Council grants worth more than \u20ac16.3 million have today been awarded to eight University of Oxford researchers for a range of cutting-edge projects.
\n \n\n\n \n 10 December 2020\n \n
\n\n \n \n \n\n \n \n \nBy testing approximately 1,000 blood donation samples each month in in the Brazilian cities of S\u00e3o Paulo and Manaus, an international team of researchers have shown that, while both cities have experienced large epidemics with high mortality, as much as three-quarters of the population in Manaus was infected between March and October, and a third of the population in S\u00e3o Paulo.
\n \n\n\n \n 10 December 2020\n \n
\n\n \n \n \n\n \n \n \nOur vaccine work is progressing quickly. To ensure you have the latest information or to find out more about the trial, please visit the Oxford COVID-19 vaccine web hub or visit the COVID-19 trial website. \r\n\r\n- Researchers show overall vaccine efficacy of 70.4% from a pooled analysis of two-dose regimen\r\n- No hospitalisations or severe disease observed in the vaccinated groups from three weeks after first dose\r\n- Efficacy results are based on data taken from 11,636 volunteers across the United Kingdom and Brazil\r\n- Data are first Phase 3 trial results of a coronavirus vaccine to be published in peer-review literature
\n \n\n\n \n 7 December 2020\n \n
\n\n \n \n \n\n \n \n \nA special concert to say thank you and pay tribute to the achievements of the Oxford vaccine team has been recorded at the Sheldonian Theatre for a film screening in time for Christmas
\n \n\n\n \n 4 December 2020\n \n
\n\n \n \n \n\n \n \n \nA new institute for nanoscience research is to open in Oxford thanks to a $10 million gift from The Kavli Foundation.
\n \n\n\n \n 26 November 2020\n \n
\n\n \n \n \n\n \n \n \nThe University of Oxford, in collaboration with AstraZeneca plc, today announces interim trial data from its Phase III trials that show its candidate vaccine, ChAdOx1 nCoV-2019, is effective at preventing COVID-19 (SARS-CoV-2) and offers a high level of protection.
\n \n\n\n \n 20 November 2020\n \n
\n\n \n \n \n\n \n \n \nNew research into the HIV-1 virus has shed light on an important factor in the evolution of viruses, which is likely also to affect SARS-CoV-2 (the virus which causes COVID-19). This new insight could have important implications for vaccine development.
\n \n\n\n \n 20 November 2020\n \n
\n\n \n \n \n\n \n \n \n \n \n\n\n \n 18 November 2020\n \n
\n\n \n \n \n\n \n \n \n \n \n\n\n \n 11 November 2020\n \n
\n\n \n \n \n\n \n \n \nThe University of Oxford has joined forces with Thermo Fisher Scientific, the world leader in serving science, to ramp up the university\u2019s capacity to deliver COVID-19 testing data.
\n \n\n\n \n 2 October 2020\n \n
\n\n \n \n \n\n \n \n \nThe University of Oxford and King Abdulaziz University (KAU) have partnered to create a new Centre for Artificial Intelligence and Precision Medicine.
\n \n\n\n \n 2 October 2020\n \n
\n\n \n \n \n\n \n \n \nNew research shows that, in a head-to-head comparison of five tests used to detect COVID-19 antibodies (known as \u2018immunoassays\u2019), an assay manufactured by Siemens and one developed by an academic partnership led by the University of Oxford had the most accurate results. The study is published in The Lancet Infectious Diseases.
\n \n\n\n \n 14 September 2020\n \n
\n\n \n \n \n\n \n \n \nThe International Severe Acute Respiratory and emerging Infection Consortium (ISARIC), based at Oxford University, in collaboration with Dr Janet Scott, of the MRC-University of Glasgow\u2019s Centre for Virus Research, has launched a longitudinal observational study to measure prevalence and risk factors of long-term health and psychosocial consequences of COVID-19. The researchers are inviting hospitals and healthcare sites worldwide to join this new study.
\n \n\n\n \n 4 September 2020\n \n
\n\n \n \n \n\n \n \n \nOxford University researchers have found that natural infection with COVID-19 produces a robust T cell response, including inducing T cell \u2018memory\u2019 to potentially fight future infections.
\n \n\n\n \n 4 September 2020\n \n
\n\n \n \n \n\n \n \n \nOxford University has topped the THE World University Rankings for a fifth consecutive year.
\n \n\n\n \n 4 September 2020\n \n
\n\n \n \n \n\n \n \n \nA new arm of the ongoing global clinical trials of the ChAdOx1 nCoV-19 vaccine led by AstraZeneca has launched in the US to assess safety, efficacy and immunogenicity of the vaccine for the prevention of COVID-19.
\n \n\n\n \n 5 August 2020\n \n
\n\n \n \n \n\n \n \n \nFour researchers from Oxford University have today received prestigious medals and prizes from the Royal Society in recognition of their outstanding contributions to science and medicine.
\n \n\n\n \n 31 July 2020\n \n
\n\n \n \n \n\n \n \n \nA team of scientists at Oxford University\u2019s Jenner Institute and Oxford Vaccine Group has taken the next step towards the discovery of a safe, effective and accessible vaccine against coronavirus.
\n \n\n\n \n 24 July 2020\n \n
\n\n \n\n \n\n \n \n \n \n Publication\n \n \n\n \n\n\n
\n \n\n \n \n \nA team from OUCRU led by Le Van Tan, Hospital for Tropical Diseases, Vietnam, and Benedikt Kessler at the Target Discovery Institute at the University of Oxford showed that lipocalin 2 is a sensitive and specific biomarker for discriminating bacterial meningitis from a broad spectrum of other brain infections, and outperforms routine CSF markers such as leukocytes, glucose, protein and lactate.
\n \n\n\n \n 17 June 2020\n \n
\n\n \n \n \n\n \n \n \nIn March 2020, the RECOVERY (Randomised Evaluation of COVid-19 thERapY) trial was established as a randomised clinical trial to test a range of potential treatments for COVID-19, including low-dose dexamethasone (a steroid treatment). Over 11,500 patients have been enrolled from over 175 NHS hospitals in the UK.
\n \n\n